NASDAQ: CSTLCastle Biosciences Inc Stock
$19.61+0.30 (+1.55%)
Updated Apr 22, 2024
CSTL Price
$19.61
Fair Value Price
$23.20
Market Cap
$538.29M
52 Week Low
$9.26
52 Week High
$26.70
P/E
-9.16x
P/B
1.38x
P/S
2.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$219.79M
Earnings
-$57.47M
Gross Margin
79.5%
Operating Margin
-26.1%
Profit Margin
-26.1%
Debt to Equity
0.16
Operating Cash Flow
-$6M
Beta
1.13
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CSTL Overview
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CSTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CSTL ($19.61) is undervalued by 15.46% relative to our estimate of its Fair Value price of $23.20 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CSTL ($19.61) is not significantly undervalued (15.46%) relative to our estimate of its Fair Value price of $23.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CSTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CSTL due diligence checks available for Premium users.
Be the first to know about important CSTL news, forecast changes, insider trades & much more!
CSTL News
Valuation
CSTL fair value
Fair Value of CSTL stock based on Discounted Cash Flow (DCF)
Price
$19.61
Fair Value
$23.20
Undervalued by
15.46%
CSTL ($19.61) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CSTL ($19.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CSTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CSTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.16x
Industry
36.48x
Market
41x
CSTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.38x
Industry
4.05x
CSTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CSTL's financial health
Profit margin
Revenue
$66.1M
Net Income
-$2.6M
Profit Margin
-3.9%
CSTL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CSTL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$453.3M
Liabilities
$62.1M
Debt to equity
0.16
CSTL's short-term assets ($295.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSTL's short-term assets ($295.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSTL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CSTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$18.6M
Investing
-$7.7M
Financing
-$3.3M
CSTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CSTL vs Diagnostic & Research Stocks
Castle Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.